Tag: M.W:300-400

875444-08-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.875444-08-9,(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,as a common compound, the synthetic route is as follows.

The chiral intermediate (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one (compound 11 in Scheme 3, prepared by procedure of WO 2007/005572) (28.0 g) is dissolved in DMF (300 mL) and cooled to – 15C. 2 M NaHMDS (39.2 mL, 1 .05 eq) was then added over 1 h, followed by addition of the biaryl chloride 7 (Scheme 3 ) (28.0 g) in DMF (50 mL), maintaining the internal temperature below -10 C. The mixture was warmed to + 12 C and was aged until complete conversion took place. Then 5M HCI (35 mL) was added, followed by 160 mL of 10% IPAC/Heptanes and 340 mL of water, keeping the temperature between 10C and 20C throughout. The layers were cut and the organic layer was washed twice with 150 mL of 1/1 DMF/water followed by two 140 mL water washes. The organic layerwas then removed under reduced pressure and the resulting residue was purified by flash chromatography (EtOAc/hexanes) to remove the excess oxazolidinone 11 (Scheme 3). The obtained colorless oil was then dissolved in refluxing heptanes (200 mL) and the solution was slowly cooled to -20 C. The resulting slurry was then stirred at -20 C for 2 hours and filtered. The filter cake was washed with cold heptanes and was then dried, yielding 44.0 g (88%) of the desired product of Formula IX (anacetrapib) as an amorphous material. The impurity (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5l-ethyl-4l-fluoro-2′-methoxy-4-(trifluoromethyl) biphenyl-2-yl)methyl)-4-methyloxazolidin-2-one (DMAP) (-3%), which is formed from 2′-(chloromethyl)-5-ethyl-4- fluoro-2-methoxy-4′-(trifluoromethyl)biphenyl (EBFCI) present in the starting material under the conditions described in Step 7, was detected in the product.

As the paragraph descriping shows that 875444-08-9 is playing an increasingly important role.

Reference£º
Patent; LEK PHARMACEUTICALS D.D.; HUMLJAN, Jan; MARAS, Nenad; WO2013/91696; (2013); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

153652-70-1, (4S,5R)-3-Benzoyl-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid is a oxazolidine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Solution OF 2-CHLOR-4, 6-DIPHENOXY-1, 3,5-triazine (CDPHT) (0. 3 g, 1 mmole) in 5 mi THF was mixed with N-methylmorpholine (0.11 ml, 1 mmole) for 30 minutes at temperature of 0-5C to obtain N- (4, 6- DIPHENOXY-1, 3, 5-triazine-2-yl)-N- methylmorpholine chloride. Then, phenyl isoserine derivative with the formula 4b, where R3= R4=CH3 (0.325 g, 1 mmol) was added and mixed for 12 hours. After N-METHYLMORPHOLINE HYDOCHLORIDE was filtered off, and solvent was evaporated it gave respective triazine ester of the formula 6b, where R3= R4=CH3, and R5=R6= OCEHG, with the quantitative yield. TLC: eluent CHCI3, RR0. 65 1H-NMR (CDCI3) : 6=1. 76 (s, 3H); 1.79 (s, 3H) ; 5.19 (d, J=8.0 Hz, 1H); 5.27 (d, J= 8. 0 Hz, 1H) ; 7.19-7. 22 (m, 2H); 7.40-7. 74 (m, 18 H) ppm] JR (KBr): 1780 [CM~1] The triazine ester, in the presence of magnesium bromide and PYROLIDINPYRIDINE, was coupled with protected Baccatin III of the generalized formula 3, where R2=Si (C2H5) 3. The product was chromatographically and SPECTRALLY identical to that described in the 11. Example.

153652-70-1, The synthetic route of 153652-70-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AGROPHARM S.A.; WO2004/56790; (2004); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.875444-08-9,(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,as a common compound, the synthetic route is as follows.

875444-08-9, [2-{[2-(t-butyldimethylsiloxy)ethyl](tetrahydro-2H-pyran-4-yl)amino}-5- (trifIuorornethyl)pyridin-3-yl]methyl methanesulfonate of step 2 and (4S,5f?)-5-[3,5- bis(trifluoromethyl)phenyl])-4-methyl-oxazolidin-2-one were used in the same manner as in step 4 of Example 3 to afford the title compound (55mg, 63%). 1H NMR (400MHz, CDCI3) 8.46 (s, 1H), 7.88 (s, 1 H), 7.77 (s, 1H), 7.73 (s, 2H), 5.72 (d, J = 8.0Hz, 1H), 4.75 (d, J = 16.0Hz, 1 H), 4.33 (d, J = 16.0Hz, 1H), 4.04-3.87 (m, 3H), 3.67 (m, 1 H), 3.50 (m, 2H), 3.38-3.17 (m, 6H), 1.91-1.72 (m, 4H), 0.78 (s, 9H), 0.61 (d, 3H), -0.03 (d, 3H).

As the paragraph descriping shows that 875444-08-9 is playing an increasingly important role.

Reference£º
Patent; DONG-A ST CO.,LTD; PARK, Jang Hyun; SONG, Seung Hyun; CHUNG, Han Kook; KIM, Heung Jae; LEE, Ji Hye; JANG, Byeong Jun; KIM, Eun Jung; JUNG, Hae Hum; RYU, Chae Lim; HWANG, Jae-Sung; LEE, Hyung Ki; KANG, Kyung Koo; KIM, Soon Hoe; WO2014/157994; (2014); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

875444-08-9, (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one is a oxazolidine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

875444-08-9, The chiral intermediate (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one (compound 11 in Scheme 3, prepared by procedure of WO 2007/005572) (28.0 g) is dissolved in DMF (300 mL) and cooled to – 15C. 2 M NaHMDS (39.2 mL, 1.05 eq) was then added over 1 h, followed by addition of the biaryl chloride 7 (Scheme 3) (28.0 g) in DMF (50 mL), maintaining the internal temperature below -10 C. The mixture was warmed to + 12 C and was aged until complete conversion took place. Then 5M HCl (35 mL) was added, followed by 160 mL of 10% IPAC/Heptanes and 340 mL of water, keeping the temperature between 10C and 20C throughout. The layers were cut and the organic layer was washed twice with 150 mL of 1/1 DMF/water followed by two 140 mL waterwashes. The organic layer was then removed under reduced pressure and the resulting residue was purified by flash chromatography (EtOAc/hexanes) to remove the excess oxazolidinone 11 (Scheme 3). The obtained colorless oil was then dissolved in refluxing heptanes (200 mL) and the solution was slowly cooled to -20 C. The resulting slurry was then stirred at -20 C for 2 hours and filtered. The filter cake was washed with cold heptanes and was then dried, yielding 44.0 g (88%) of the desired product of Formula IX (anacetrapib) as an amorphous material. The impurity (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5′-ethyl-4′-fluoro-2′-methoxy-4-(trifluoromethyl) biphenyl-2-yl)methyl)-4-methyloxazolidin-2-one (DMAP) (?3%), which is formed from 2′-(chloromethyl)-5-ethyl-4-fluoro-2-methoxy-4′-(trifluoromethyl)biphenyl (EBFCI) present in the starting material under the conditions described in Step 7, was detected in the product.

875444-08-9 (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one 23583229, aoxazolidine compound, is more and more widely used in various fields.

Reference£º
Patent; LEK Pharmaceuticals d.d.; EP2468735; (2012); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

875444-08-9,875444-08-9, (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one is a oxazolidine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of (45,5J?)-5-[3;5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one (12.00 g, 38.3 mmol) in THF (200 mL) was cooled to 0 C. NaH (0.919 g, 38.3 mmol) was added. The mixture was stirred at 0 C for 30 min. The title compound from Step A (10.0 g, 31.9 mmol) in THF (30 mL) was added. The mixture was stirred at 0 C and then room temperature for 4 h. Saturated NH C1 (10 mL) was added. The mixture was extracted with ethyl acetate (3 xlOO mL). The combined organic fractions were washed with brine (saturated, 20 mL), dried (Na2S0 ), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel Biotage 65i, eluting with EtOAc/hexane (20/80) to give the title compound as a colorless solid. NMR (CDCl3s 500 MHz) delta 8.57 (s, 1H), 7.94 (s, 1H), 7.82 (s, 2H), 5.86 (d, J= 8.5 Hz, 1H), 4.97 (d, J- 18.0 Hz, 1H), 4.46 (m5 1H), 4.28 (d, J= 17.5 Hz, 1H), 2.60 (s, 3H), 0.83 (d, J= 6.5 Hz 3H)

As the paragraph descriping shows that 875444-08-9 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; LU, Zhijian; CHEN, Yi-Heng; SMITH, Cameron; LI, Hong; THOMPSON, Christopher, F.; SWEIS, Ramzi; SINCLAIR, Peter; KALLASHI, Florida; HUNT, Julianne; ADAMSON, Samantha, E.; DONG, Guizhen; ONDEYKA, Debra, L.; QIAN, Xiaoxia; SUN, Wanying; VACHAL, Petr; ZHAO, Kake; WO2012/58187; (2012); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

875444-08-9,875444-08-9, (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one is a oxazolidine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The chiral intermediate (4S,5R)-5-[3 ,5-Bis(trifluoromethyl)rhohenyl]-4-methyl-l ,3- oxazolidin-2-one (11) which was made above is dissolved in DMF (2.8 kg in 32.7 L) and cooled to -15 C. 2.0 M NaHMDS (3.92 L, 1.05eq) was then added over 1.5 hr, followed by addition of the biaryl chloride 7 (2.8kg) in DMF. The mixture was warmed to +12C and was aged until complete conversion took place. Then 5N HCl (3.4L) was added, followed by 16L of 10%IPAC/Heptane and 34L of water, keeping the temperature between 100C and 200C throughout. The layers were cut and the organic layer was washed twice with 14L of 1:1 DMF:water followed by two 14L water washes. The organic layer was assayed for yield and was then filtered through 2.4 kg of silica gel to remove the excess oxazolidinone to <0.5%. The silica was washed with 5% IPAC/Heptane. The combined organic solutions were distilled to remove IPAC to <1%. The warm heptane solution was then transferred slowly into a 200C heptane solution containing 10 wt% seed. The slurry was then cooled to -200C and filtered. The filter cake was washed with cold heptane and was then dried, yielding the desired product 12. The synthetic route of 875444-08-9 has been constantly updated, and we look forward to future research findings. Reference£º
Patent; MERCK & CO., INC.; WO2007/92642; (2007); A2;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.875444-08-9,(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,as a common compound, the synthetic route is as follows.,875444-08-9

The chiral intermediate (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one (compound of formula XV; cf. also compound 11 in Scheme 3) (280 mg) prepared by procedure of WO 2007/005572 is dissolved in DMF (30 mL) and cooled to -15C. 2 M NaHMDS (3.90 mL, 1.05 eq) was then added over 1 h, followed by addition of the biaryl chloride EBFCI (270 mg) in DMF (5 mL), maintaining the internal temperature below-10 C. The mixture was warmed to +12 C and was aged until complete conversion took place. Then 5M HCl (3.5 mL) was added, followed by 20 mL of 10% IPAC/Heptanes and 40 mL of water, keeping the temperature between 10C and 20C throughout. The layers were cut and the organic layer was washed twice with 20 mL of 1/1 DMF/water followed by two 15 mL water washes. The organic layer was then removed under reduced pressure and the resulting residue was purified by flash chromatography (EtOActhexanes) to remove the excess oxazolidinone (compound of formula XV). The pure (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5′-ethyl-4′-fluoro-2′-methoxy-4-(trifluoromethyl)biphenyl-2-yl)methyl)-4-methyloxazolidin-2-one (DMAP, compound of formula XII”) was obtained as a colorless oil (388 mg, 80%).

The synthetic route of 875444-08-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; LEK Pharmaceuticals d.d.; EP2468736; (2012); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.875444-08-9,(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,as a common compound, the synthetic route is as follows.

875444-08-9, Step 7: Synthesis of (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2- ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl- 1, 3-oxazolidin-2-one (anacetrapib); The chiral intermediate (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one (compound of formula XV; cf. also compound 11 in Scheme 3) (28.0 g) prepared by the procedure of WO 2007/005572 is dissolved in DMF (300 mL) and cooled to -15C. 2 M NaHMDS (39.2 mL, 1 .05 eq) was then added over 1 h, followed by addition of the biaryl chloride 7 (Scheme 3 ) (28.0 g) in DMF (50 mL), maintaining the internal temperature below – 10 C. The mixture was warmed to + 12 C and was aged until complete conversion took place. Then 5M HCI (35 mL) was added, followed by 160 mL of 10% IPAC/Heptanes and 340 mL of water, keeping the temperature between 10C and 20C throughout. The layers were cut and the organic layer was washed twice with 150 mL of 1/1 DMF/water followed by two 140 mL water washes. The organic layer was then removed under reduced pressure and the resulting residue was purified by flash chromatography (EtOAc/hexanes) to remove the excess oxazolidinone 11 (Scheme 3). The obtained colorless oil was then dissolved in refluxing heptanes (200 mL) and the solution was slowly cooled to -20 C. The resulting slurry was then stirred at -20 C for 2 hours and filtered. The filter cake was washed with cold heptanes and was then dried, yielding 44.0 g (88%) of the desired product of compound of formula XV” (anacetrapib) as an amorphous material. An impurity of compound of formula XVII” (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,-ethyl-4,-fluoro-2′- methoxy-4-(trifluoromethyl) biphenyl-2-yl)methyl)-4-methyloxazolidin-2-one (DMAP) is present in the thus obtained anacetrapib in an amount of about 3 % by weight relative to the total amount of anacetrapib product. DMAP originates from 2′-(chloromethyl)-5-ethyl-4-fluoro-2-methoxy-4′-(trifluoromethyl)biphenyl (EBFCI) representing an impurity which forms in the preparation path of 2′-(chloromethyl)-4-fluoro-5-isopropyl-2-methoxy- 4′-(trifluoromethyl)biphenyl under the above described conditions.

875444-08-9 (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one 23583229, aoxazolidine compound, is more and more widely used in various fields.

Reference£º
Patent; LEK PHARMACEUTICALS D.D.; HUMLJAN, Jan; MARAS, Nenad; WO2012/85133; (2012); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1676-86-4,(S)-Benzyl (4-(2,5-dioxooxazolidin-4-yl)butyl)carbamate,as a common compound, the synthetic route is as follows.

1676-86-4, The affinity peptides (obtained from SynPep Corporation, Dublin, Calif.) were dried under vacuum. A dried 40 mL glass vial fitted with a silicone rubber septum and magnetic stirring bar was charged with 15 mL of dry DMF. The dried, affinity peptide, as indicated in Table 1, was added to the vial and the contents were stirred until the peptide was completely dissolved. The vial was then placed into a heated aluminum block with stirring and the contents were allowed to equilibrate to a temperature of 50 C. Then, epsilon-carbobenzyloxylysine N-carboxyanhydride (CbzLys), prepared as described above, was added as a 1 mmol/mL solution in dry DMF, as shown in Table 1, and the contents were allowed to stir for 4 h. The remaining epsilon-carbobenzyloxylysine N-carboxyanhydride, also in DMF, was injected, as shown in Table 1, and the reactants were allowed to stir at 50 C. for 72 h. The product was collected by evaporating the solvent, washing with hexanes, and then drying in vacuum. Samples of the product were analyzed using MALDI mass spectrometry to confirm the presence of the desired product. The results of the analysis are given in Table 2.

As the paragraph descriping shows that 1676-86-4 is playing an increasingly important role.

Reference£º
Patent; O’Brien, John P.; US2007/22547; (2007); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem

875444-08-9,875444-08-9, (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one is a oxazolidine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4- methyloxazolidin-2-one (46g, 147mol), obtained in step 2, in DMF (150ml) was dropwise added NaHMDS (sodium hexamethyldisilazide) (176 ml, 176 mol) at -40C. The reaction mixture was stirred for 30 min, and slowly added with drops of a dilution of 2-chloro-5- (trifluoromethyl)pyridin-3-yl-methane chloride, obtained in step 1 , in DMF (30ml). The resulting reaction mixture was heated to room temperature, stirred for 3 hrs, diluted with ethyl acetate (200 ml), and added with water (500 ml) to terminate the reaction. The organic layer thus formed was withdrawn, washed with water (2.5 I), and filtered through silica-selite pad at a reduced pressure to afford the title compound (60g, 67%). 1 H NMR (400MHz, CDCI3) . 8.64 (s, 1 H), 8.01 (s, 1 H), 7.90 (s, 1 H), 7.82 (s, 2H), 5.76 (d, J = 8.0Hz, 1 H), 4.84 (d, J = 16.0Hz, 1 H), 4.47 (d, J = 16.4Hz, 1 H), 4.22 (m, 1 H), 083 (d, 3H).

The synthetic route of 875444-08-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DONG-A ST CO.,LTD; PARK, Jang Hyun; SONG, Seung Hyun; CHUNG, Han Kook; KIM, Heung Jae; LEE, Ji Hye; JANG, Byeong Jun; KIM, Eun Jung; JUNG, Hae Hum; RYU, Chae Lim; HWANG, Jae-Sung; LEE, Hyung Ki; KANG, Kyung Koo; KIM, Soon Hoe; WO2014/157994; (2014); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem